Superworth

Spectral AI MDAI

Medical - Instruments & Supplies, Healthcare
$1.44
−4.00%
Market cap
$46.3M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
3.0×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$15.4M
−44% on a year ago
Net margin
−65.5%
Free cash flow yield
n/m
not a meaningful number

Spectral AI trades at 3.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $15.4M over the last twelve months, down 44% on a year earlier with a −66% net margin.

Charts

Financials

Income statement for MDAI, by quarter
Income statementQ3 FY23Q4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
$3.4M−51%$5.3M−13%$6.3M+25%$7.5M+76%$8.2M+138%$7.6M+44%$6.7M+6%$5.1M−32%$3.8M−54%$4.1M−46%$4M−41%$3.5M−30%
Cost of revenue$2M−48%$2.9M−21%$3.4M+17%$4.2M+69%$4.5M+129%$4.3M+49%$3.5M+5%$2.8M−33%$2.2M−52%$2.2M−47%$2M−45%$2.4M−13%
Gross profit$1.5M−54%$2.4M−3%$2.9M+35%$3.3M+85%$3.7M+149%$3.3M+37%$3.2M+8%$2.3M−31%$1.6M−56%$1.8M−45%$2M−36%$1.1M−51%
R&Dn/an/an/an/an/an/an/a$1.5Mn/an/an/a$1.7M+16%
SG&A$5.6M+62%$5.4M+1688%$5.1M+0%$5.8M+20%$4.6M−19%$4.5M−17%$4.1M−20%$3M−49%$5M+9%$4.1M−8%$4M−2%$3.7M+27%
−$4.2M+1560%−$2.9M+66%−$2.1M−26%−$2.4M−18%−$886K−79%−$1.1M−62%−$896K−58%−$2.1M−13%−$3.3M+277%−$2.2M+102%−$2M+120%−$4.3M+104%
Interest expensen/an/an/an/a$8Kn/a$20K$397K$300K+3650%$289K$258K+1190%$378K−5%
Pre-tax income−$10.7M+3521%−$3.6M−$3.2M−11%−$2.8M−8%−$1.5M−86%−$7.6M+113%$3M−$8M+186%−$3.5M+142%$1M−$3.4M−$4M−50%
−$54K−$21K$22K−52%$69K+73%$37K$143K$71K+223%−$19K$2K−95%−$43K−$10K$170K
Net income−$10.6M+2697%−$3.5M−$3.2M−11%−$2.9M−7%−$1.5M−86%−$7.6M+114%$2.9M−$8M+178%−$3.6M+136%$1.1M−$3.4M−$4.2M−48%
−$0.77+2467%−$0.22−$0.19−30%−$0.16−30%−$0.08−90%−$0.39+77%$0.11−$0.31+94%−$0.13+63%$0.03−$0.11−$0.13−58%
13.8M+5%16.1M+22%16.6M+26%17.6M+33%17.9M+29%19.7M+22%24M+45%25.4M+45%26.3M+47%30.6M+55%31.8M+32%32.1M+26%

EPS, diluted: 11 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 3 periods, Q4 FY21 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Instruments & Supplies nearest Spectral AI's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
MDAISpectral AI$46.3Mn/m22.8×3.0×−44%−65.5%
NEPHNephros$38.3M22.1×28.4×1.9×+24%8.4%
APTAlpha Pro Tech$56.7M13.6×14.8×0.9×+6%6.8%
KEQUKewaunee Scientific$94.9M11.9×13.7×0.3×+5%3.0%
PDEXPro DEX$199.3M15.1×16.6×2.6×+16%17.6%
UTMDUtah Medical Products$236.3M22.6×20.9×6.5×−7%29.0%
INFUInfuSystem$277.6M34.0×43.5×1.9×+2%6.0%
EMBCEmbecta$380.2M4.6×11.7×0.4×−8%8.6%
Peer median$199.3M15.1×16.6×1.9×+5%8.4%

More on Spectral AI

Each number over time

Its groups

About

Industry
Medical - Instruments & Supplies
Sector
Healthcare

Valuation data, not investment advice. Prices as of .